NOVNEE Stock Price and Chart — SIX:NOVNEE — TradingView

Overview

Financials News Ideas Discussions Technicals Seasonals Bonds

NOVNEE chart

Key facts today

Novartis gained US FDA approval for Pluvicto, a prostate cancer drug, after phase 3 trial results showed a 59% reduction in progression risk, potentially tripling eligible patients.

Novartis is developing pelacarsen, an injectable treatment for elevated lipoprotein(a) (Lp(a)), a genetic heart disease risk factor, in a market lacking approved therapies.

Novartis appointed Karen Hale as Chief Legal and Compliance Officer, effective April 14, after Klaus Moosmayer left to explore other opportunities.

Analyze the impact Analyze the impact

Key stats

Employees

About NOVARTIS N

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Financials

Performance

Revenue to profit conversion

Debt level and coverage

Earnings

Next:—

No news here

Looks like there's nothing to report right now

Ideas

See all ideas

Technicals

Summarizing what the indicators are suggesting.

Oscillators

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Oscillators

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Summary

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Summary

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Summary

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Moving Averages

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Moving Averages

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Seasonals

Displays a symbol's price movements over previous years to identify recurring trends.

NOVNEE highest yielding bonds

6.55%

Aug 14, 2050

5.79%

Sep 21, 2042

5.75%

Nov 20, 2045

5.66%

Sep 18, 2054

5.59%

May 6, 2044

4.95%

Sep 18, 2034

4.61%

Aug 14, 2030

4.58%

Sep 18, 2031

4.54%

Nov 20, 2025

4.36%

Sep 18, 2029

4.20%

May 17, 2027

See all NOVNEE bonds

Curated watchlists where NOVNEE is featured.

Big pharma stocks: Top pharmaceutical firms

Cancer research stocks: Oncology pharmaceutical market

See all sparks

The current price of NOVNEE is 98.12 CHF — it has increased by 0.48% in the past 24 hours. Watch NOVARTIS N 2. LINIE stock price performance more closely on the chart.

Depending on the exchange, the stock ticker may vary. For instance, on SIX exchange NOVARTIS N 2. LINIE stocks are traded under the ticker NOVNEE.

NOVNEE stock has fallen by −0.71% compared to the previous week, the month change is a 0.54% rise, over the last year NOVARTIS N 2. LINIE has showed a 12.60% increase.

NOVNEE reached its all-time high on Jul 20, 2015 with the price of 103.03 CHF, and its all-time low was 47.88 CHF and was reached on Mar 19, 2008. View more price dynamics on NOVNEE chart.
See other stocks reaching their highest and lowest prices.

NOVNEE stock is 0.95% volatile and has beta coefficient of 0.93. Track NOVARTIS N 2. LINIE stock price on the chart and check out the list of the most volatile stocks — is NOVARTIS N 2. LINIE there?

Today NOVARTIS N 2. LINIE has the market capitalization of ‪187.14 B‬, it has increased by 3.03% over the last week.

Yes, you can track NOVARTIS N 2. LINIE financials in yearly and quarterly reports right on TradingView.

NOVNEE net income for the last quarter is ‪2.47 B‬ CHF, while the quarter before that showed ‪2.76 B‬ CHF of net income which accounts for −10.52% change. Track more NOVARTIS N 2. LINIE financial stats to get the full picture.

No, NOVNEE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.

As of Mar 31, 2025, the company has ‪75.88 K‬ employees. See our rating of the largest employees — is NOVARTIS N 2. LINIE on this list?

EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVARTIS N 2. LINIE EBITDA is ‪18.90 B‬ CHF, and current EBITDA margin is 42.40%. See more stats in NOVARTIS N 2. LINIE financial statements.

Like other stocks, NOVNEE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVARTIS N 2. LINIE stock right from TradingView charts — choose your broker and connect to your account.

Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NOVARTIS N 2. LINIE technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NOVARTIS N 2. LINIE stock shows the buy signal. See more of NOVARTIS N 2. LINIE technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.